Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

View Full Paper
Ask AI
Bookmark
Share

Authors

CHCraig C. HofmeisterBBB. BurtonLBLawrence Boise

Discussion

Loading...

Member takes

Overview

Randomized trial shows enhanced response rates in multiple myeloma with daratumumab and ixazomib, indicating safety without compromising efficacy.

Key Points

  • Evaluate the safety and efficacy of non-IMID based daratumumab-combination induction therapies in multiple myeloma.
  • Randomized Phase II study comparing two treatment arms: DId and DVd.
  • Transplant-eligible patients received autologous stem cell transplant after cycle 8.
  • Primary endpoint was VGPR rate after 8 induction cycles.
  • Arm B (daratumumab, bortezomib, dexamethasone) showed higher VGPR rates (56.5%) compared to Arm A (28%).
  • Overall response rate was 95.7% for Arm B vs 76% for Arm A.
  • Median PFS was not reached for either arm, with 40-month PFS rates of 90% in Arm B.

Cite This Study

Hofmeister et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d15dhttps://doi.org/10.1182/blood-2025-5843
View Full Paper
Ask AI
Bookmark
Share